Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens | Zendy

Martti Vaara | Zendy; Hélio S. Sader | Zendy; Paul R. Rhomberg | Zendy; R. N. Jones | Zendy; Timo Vaara | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens

Author(s) -

Martti Vaara,

Hélio S. Sader,

Paul R. Rhomberg,

R. N. Jones,

Timo Vaara

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks438

Subject(s) - polymyxin b , polymyxin , microbiology and biotechnology , pseudomonas aeruginosa , acinetobacter , acinetobacter baumannii , broth microdilution , klebsiella pneumoniae , colistin , antimicrobial , biology , antibiotics , minimum inhibitory concentration , bacteria , escherichia coli , biochemistry , genetics , gene

In spite of reported nephrotoxicity, polymyxins have been reinstated as the last-line therapy to treat infections caused by Gram-negative bacterial strains that are resistant to other agents. NAB739 has a cyclic portion identical to that of polymyxin B, but its linear peptide portion consists of threonyl-d-serinyl instead of diaminobutyryl-threonyl-diaminobutyryl. Therefore, NAB739 lacks both of the positive charges present in the linear part of polymyxin B. Here, we compare the antibacterial activity of NAB739 with that of polymyxin B against a representative collection of contemporary Gram-negative bacteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research